The ADME properties of therapeutic peptides and proteins have been improved significantly and bio-therapeutic drugs have gained importance in the treatment of critical diseases. As in small molecule drug development there is a need to understand their bio-transformations to ensure that the molecule is safe and efficacious and does not cause toxicity. The ability to find, identify and confirm catabolites as quickly as possible is critical at multiple stages of drug discovery and development. Advancements in accurate mass instrumentation such as the TripleTOF® 6600 have enabled the generation of very information rich raw data but new software to automate the catabolite identification workflow is required to benefit drug metabolism researchers. To address this need SCIEX has introduced the new MetabolitePilotTM 2.0 software that includes a dedicated peptide catabolism workflow.
In this tech note the in-vitro metabolism of a model therapeutic peptide Bivalirudin was investigated to highlight the new peptide catabolism workflow features of MetabolitePilot 2.0 software.
To download your copy of this technical note complete the form opposite.
Registrants for this application note are covered by the Eclipse Business Media Privacy Policy.
By submitting your information, you agree that SCIEX may collect and further process your personal data in accordance with its Privacy Policy.
Eclipse Business Media Ltd, Regd in England, No. 06513189, Woodview, Bull Lane Industrial Estate, Sudbury, CO10 0FD, United Kingdom, T +44 (0)161 818 7434, info@sepscience.com
Eclipse Business Media Ltd needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy or contact privacy@labxmediagroup.com
Copyright © 2023. All rights reserved